

**Smurf1-targeting miR-19b-3p-modified BMSCs combined PLLA composite
scaffold to enhance osteogenic activity and treat critical-sized bone defects**

Ao Xiong^{1, 2}, Yijun He³, Liang Gao⁴, Guoqing Li^{1, 2}, Jian Weng^{1, 2}, Bin Kang^{1, 2}, Deli Wang^{1, 2*}, Hui Zeng^{1, 2*}

1.Department of Bone & Joint Surgery, Peking University Shenzhen Hospital, Shenzhen, PR China, 518036.

2.National & Local Joint Engineering Research Center of Orthopaedic Biomaterials, Peking University Shenzhen Hospital, Shenzhen, PR China, 518036.

3.Translational Research Centre of Regenerative Medicine and 3D Printing of Guangzhou Medical University, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, PR China, 510150.

4.Center of Experimental Orthopaedics, Saarland University Medical Center, Homburg, Germany, D-66421.

* Corresponding authors: Deli Wang (wangdelinavy@163.com) and Hui Zeng (zenghui_36@163.com)




Figure S1. The identification of BMSCs via the quantitative detection of CD29, CD44, CD34 and CD45 protein expression using flow cytometer method.




Figure S2. The detailed information about the Lentivirus plasmid.